BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

British Journal of Ophthalmology 2005;89:1293-1297; doi:10.1136/bjo.2005.067637
Copyright © 2005 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Italian Translation
Right arrow German translation
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fuchsjäger-Mayrl, G
Right arrow Articles by Schmetterer, L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fuchsjäger-Mayrl, G
Right arrow Articles by Schmetterer, L

EXTENDED REPORT

Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension

G Fuchsjäger-Mayrl1,2, B Wally1, G Rainer2, W Buehl2, T Aggermann1, J Kolodjaschna1, G Weigert1, E Polska1, H-G Eichler1, C Vass2, L Schmetterer1,3

1 Department of Clinical Pharmacology, Medical University of Vienna, Austria
2 Department of Ophthalmology, Medical University of Vienna, Austria
3 Institute of Medical Physics, Medical University of Vienna, Austria

Correspondence to:
Correspondence to:
Dr L Schmetterer
Department of Clinical Pharmacology, Währinger Gürtel 18-20, A-1090 Vienna, Austria; Leopold.Schmetterer{at}meduniwien.ac.at

Background: There is evidence that perfusion abnormalities of the optic nerve head are involved in the pathogenesis of glaucoma. There is therefore considerable interest in the effects of topical antiglaucoma drugs on ocular blood flow. A study was undertaken to compare the ocular haemodynamic effects of dorzolamide and timolol in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT).

Methods: One hundred and forty patients with POAG or OHT were included in a controlled, randomised, double blind study in two parallel groups; 70 were randomised to receive timolol and 70 to receive dorzolamide for a period of 6 months. Subjects whose intraocular pressure (IOP) did not respond to either of the two drugs were switched to the alternative treatment after 2 weeks. Scanning laser Doppler flowmetry was used to measure blood flow in the temporal neuroretinal rim and the cup of the optic nerve head. Pulsatile choroidal blood flow was assessed using laser interferometric measurement of fundus pulsation amplitude.

Results: Five patients did not respond to timolol and were changed to the dorzolamide group, and 18 patients changed from dorzolamide treatment to timolol. The effects of both drugs on IOP and ocular perfusion pressure were comparable. Dorzolamide, but not timolol, increased blood flow in the temporal neuroretinal rim (8.5 (1.6)%, p<0.001 versus timolol) and the cup of the optic nerve head (13.5 (2.5)%, p<0.001 versus timolol), and fundus pulsation amplitude (8.9 (1.3)%, p<0.001 versus timolol).

Conclusions: This study indicates augmented blood flow in the optic nerve head and choroid after 6 months of treatment with dorzolamide, but not with timolol. It remains to be established whether this effect can help to reduce visual field loss in patients with glaucoma.


Abbreviations: FPA, fundus pulsation amplitude; HRF, Heidelberg retina flowmeter; IOP, intraocular pressure; OHT, ocular hypertension; ONH, optic nerve head; OPP, ocular perfusion pressure; POAG, primary open angle glaucoma; SLDF, scanning laser Doppler flowmetry

Keywords: dorzolamide; timolol; ocular blood flow; glaucoma; ocular hypertension







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd.